Figure 2. Geographical Distribution of Mean Number of Anti–Vascular Endothelial Growth Factor Injections per 1000 Medicare Part B Beneficiaries in 2015 for Aflibercept, Ranibizumab, and Bevacizumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.